Dr. Lal PathLabs’ board has approved a bonus issue of 1:1, a ₹7 per share interim dividend, and a new employee stock option plan (ESOP). The board also approved an increase in authorized share capital and the voluntary liquidation of Suburban Diagnostics. These decisions aim to reward shareholders, incentivize employees, and streamline operations. The record date for the interim dividend is November 7, 2025.
Key Approvals and Announcements
The board of directors at Dr. Lal PathLabs has approved several key initiatives during their meeting on October 31, 2025, designed to benefit shareholders and employees while optimizing the company’s structure.
Bonus Issue Details
A bonus issue has been approved in the ratio of 1:1, meaning one bonus equity share for every one fully paid-up equity share held. This is subject to shareholder and regulatory approvals.
Interim Dividend Declaration
The board has declared a second interim dividend of ₹7 per equity share (at 70% on a face value of ₹10 each) for the financial year 2025-26. The record date for determining eligibility is November 7, 2025, and the dividend will be dispatched within 30 days of declaration.
Employee Stock Option Plan
A new employee restricted stock unit plan called “Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025” (“RSU 2025”) has been introduced. The plan reserves options/shares by reducing the options/shares reserve from the existing “Dr. Lal PathLabs Employee Stock Option Plan 2022” (“ESOP 2022”), subject to shareholder approval.
Increase in Authorized Share Capital
The authorized share capital will increase from INR 1,07,96,00,000 to INR 2,00,00,00,000, divided into 20,00,00,000 equity shares of INR 10 each, subject to member approval.
Voluntary Liquidation of Subsidiary
Suburban Diagnostics (India) Private Limited will undergo voluntary liquidation. The business undertaking will be distributed to the Parent Company on a going concern basis.
Financial Performance: Q2 2026 (Jul-Sep)
The company posted a profit of ₹1,522 million. Revenue from operations was ₹7,306 million for Q2 2026.
Source: BSE
